Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives $12.90 Consensus Target Price from Analysts

Compass Therapeutics, Inc. (NASDAQ:CMPX) has been assigned an average recommendation of “Moderate Buy” from the eleven analysts that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, nine have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $12.90.

Several equities analysts have recently issued reports on the company. Wall Street Zen raised Compass Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Compass Point set a $10.00 target price on shares of Compass Therapeutics in a research report on Monday, October 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Compass Therapeutics in a research report on Wednesday, October 8th. D. Boral Capital reissued a “buy” rating and set a $30.00 price target on shares of Compass Therapeutics in a research note on Wednesday, November 5th. Finally, Lifesci Capital began coverage on shares of Compass Therapeutics in a report on Monday, October 6th. They issued an “outperform” rating and a $10.00 price objective on the stock.

Institutional Investors Weigh In On Compass Therapeutics

A number of institutional investors have recently made changes to their positions in CMPX. Vivo Capital LLC lifted its stake in Compass Therapeutics by 57.9% in the third quarter. Vivo Capital LLC now owns 9,545,466 shares of the company’s stock valued at $33,409,000 after buying an additional 3,502,000 shares during the period. Millennium Management LLC raised its position in shares of Compass Therapeutics by 280.4% in the 3rd quarter. Millennium Management LLC now owns 3,237,572 shares of the company’s stock valued at $11,332,000 after acquiring an additional 2,386,367 shares during the period. Focus Partners Wealth boosted its stake in Compass Therapeutics by 16.2% during the 3rd quarter. Focus Partners Wealth now owns 15,805 shares of the company’s stock worth $56,000 after acquiring an additional 2,206 shares during the last quarter. Citadel Advisors LLC boosted its stake in Compass Therapeutics by 1,981.2% during the 3rd quarter. Citadel Advisors LLC now owns 233,271 shares of the company’s stock worth $816,000 after acquiring an additional 245,671 shares during the last quarter. Finally, Brevan Howard Capital Management LP acquired a new position in Compass Therapeutics during the third quarter valued at approximately $161,000. 68.43% of the stock is owned by institutional investors and hedge funds.

Compass Therapeutics Price Performance

CMPX opened at $4.89 on Thursday. Compass Therapeutics has a one year low of $1.27 and a one year high of $5.05. The company’s 50 day simple moving average is $3.93 and its 200-day simple moving average is $3.11. The stock has a market capitalization of $869.74 million, a P/E ratio of -10.87 and a beta of 1.48.

Compass Therapeutics (NASDAQ:CMPX) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.06. As a group, analysts anticipate that Compass Therapeutics will post -0.36 EPS for the current year.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.